Vericel Corporation: Q1 2020 Form 10-Q Summary
Business Context and Reporting Period
Vericel is a commercial-stage biopharmaceutical company focused on advanced cell therapies. Its marketed products are MACI, for repair of knee cartilage defects, and Epicel, for severe burns. The company also holds North American rights to NexoBrid, which remained in clinical development. The filing covers the unaudited three months ended March 31, 2020, with comparisons to the same period in 2019.
Financial Results and Liquidity
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Net product sales | $26.7 million | $21.8 million | Up approximately 22% |
| Gross profit | $16.8 million | $13.2 million | Up approximately 27% |
| Gross margin | 63% | 60% | Up 3 percentage points |
| Operating expenses | $21.8 million | $16.5 million | Up approximately 32% |
| Loss from operations | $5.1 million | $3.4 million | Loss increased |
| Net loss | $4.7 million | $2.8 million | Loss increased |
| Basic and diluted loss per share | $0.10 | $0.07 | Loss increased |
| Operating cash flow | $4.7 million provided | $0.2 million provided | Improved |
MACI revenue was $20.3 million versus $16.6 million, while Epicel revenue was $6.4 million versus $5.2 million. Product sales growth reflected volume increases in both products, although COVID-19-related cancellations reduced MACI implant volume by approximately 9% for procedures scheduled between March 15 and March 31.
Cash, cash equivalents and restricted cash totaled $45.7 million at March 31, 2020. Short-term and long-term investments totaled $37.7 million, resulting in approximately $83.4 million of cash and investments. The company had no material debt reported; operating lease liabilities totaled $27.1 million. Accounts receivable declined to $24.2 million from $32.2 million at year-end 2019, while inventory increased to $7.3 million.
Cash increased by $18.7 million during the quarter, primarily from $13.7 million of investing cash inflow associated with investment maturities and $4.7 million of operating cash flow. The company stated that existing cash, cash equivalents and investments should support current operations for at least 12 months from issuance of the financial statements.
Material Changes Versus the Prior Comparable Period
- Revenue increased $4.9 million, led by higher MACI and Epicel sales.
- Gross margin improved from 60% to 63%, primarily because manufacturing costs are largely fixed relative to sales volume.
- Research and development expense increased to $3.8 million from $3.0 million, including $0.6 million related to NexoBrid.
- Selling, general and administrative expense increased to $18.1 million from $13.5 million, driven by sales-force expansion, higher stock compensation, patient reimbursement support, salaries and Epicel commercial expenses.
- Stock-based compensation increased to $3.8 million from $2.6 million and represented a significant non-cash expense.
- Net loss widened despite revenue growth because operating expenses increased faster than gross profit.
- Interest income declined to $0.3 million from $0.5 million due primarily to lower investment returns.
Guidance, Outlook, Risks and Unusual Items
- The company did not provide a specific revenue or earnings forecast in the filing.
- COVID-19 materially affected MACI demand through elective-surgery restrictions, procedure cancellations, slower new orders, hospital access limitations and potential reimbursement pressure. Management expected near-term weakness to continue, but the duration and extent were unclear.
- Epicel was expected to be less directly affected because it treats severe burns, although reduced trauma admissions could affect demand.
- Management continued to manufacture MACI and Epicel and reported safety stock of key raw materials. No material supply-chain interruption or shipping delay had occurred as of the filing date, but the short product shelf lives and dependence on air and courier transportation create delivery risk.
- Management targeted a mid-2020 FDA biologics license application submission for NexoBrid, while noting that the pandemic could delay regulatory review. Potential NexoBrid payments include $7.5 million upon U.S. approval and up to $125 million tied to sales milestones; these payments were not yet probable at March 31, 2020.
- The company implemented a temporary hiring moratorium, remote-work measures, travel restrictions and reductions in non-essential discretionary spending. Layoffs, furloughs or salary reductions remained possible if pandemic conditions persisted.
- If elective-surgery restrictions continued for 12 months or longer, the company might need additional capital and might be unable to obtain financing on acceptable terms. Any financing could dilute shareholders or adversely affect shareholder rights.
- Revenue included a $1.2 million favorable adjustment for prior-period implant estimates, primarily following completion of the late-2019 billing claims process. The accounts receivable allowance for uncollectible consideration was $3.5 million; a 0.5% change in the estimated uncollectible rate could affect quarterly revenue by approximately $0.5 million.
- No material legal proceedings or off-balance-sheet arrangements were reported. Management concluded that disclosure controls were effective and that there were no material changes in internal control over financial reporting.
Important Facts for Investors to Verify
- Whether MACI procedure volumes and new orders recovered as elective surgeries resumed, and the extent of any subsequent COVID-19 disruptions.
- Whether the company maintained positive operating cash flow after the temporary benefit from collecting $8.0 million of accounts receivable during the quarter.
- The sustainability of the 63% gross margin amid lower procedure volumes and potential inventory or manufacturing impairments.
- Progress and timing of the NexoBrid BLA submission, FDA review and related milestone obligations.
- Changes in payer collections, accounts receivable allowances and patient reimbursement exposure.
- Whether cash and investments remained sufficient for at least 12 months without additional equity financing or other capital.